#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
“What we’re seeing with consolidated cannabis companies mirrors tobacco industry tactics from decades past: aggressive marketing to vulnerable populations, dosing products that deliberately exceed therapeutic ranges, and a systematic gap between what the lab reports say and what consumers actually receive. My patients deserve the same product transparency and safety standards we demand from pharmaceutical manufacturers, and until we establish real regulatory parity, I tell them to approach commercial cannabis with the same scrutiny they’d apply to any unproven medicine.”
💼 While comparisons between cannabis and tobacco industries raise important regulatory concerns, clinicians should recognize that the underlying pharmacology and disease mechanisms differ substantially, making direct parallels incomplete. The allegations of misleading marketing practices—whether about product potency, health effects, or safety profiles—do warrant clinical attention, particularly given the gaps in long-term safety data and the variability in product formulations now available to patients. Confounders in evaluating these claims include the nascent state of cannabis research, inconsistent state-level regulation, and difficulty distinguishing between industry misconduct and genuine scientific uncertainty about therapeutic effects. Rather than treating cannabis as either a medicinal panacea or a threat equivalent to tobacco, clinicians should maintain a cautious, evidence-based approach: counsel patients that marketing claims often outpace evidence, document baseline use patterns and motivations, and stay informed about emerging safety signals while awaiting higher-quality outcome data.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
